ArticlePPAR research2014
The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels.
Article in PPAR research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Dual-Caspase-Mediated Apoptosis Underlies Peritoneal Cell-Free DNA Release After PD-Related Peritonitis.Genes · 2026Article
- Review
- NETosis and kidney disease: what do we know?International urology and nephrology · 2023Review
- Cell-free DNA as a potential biomarker for acute myocardial infarction: A systematic review and meta-analysis.International journal of cardiology. Heart & vasculature · 2023Review
- NETs-Induced Thrombosis Impacts on Cardiovascular and Chronic Kidney Disease.Circulation research · 2023Review
- Review
- The Citrullination-Neutrophil Extracellular Trap Axis in Chronic Diseases.Journal of innate immunity · 2022Review
- Donor-derived cell-free DNA is associated with cardiac allograft vasculopathy.Clinical transplantation · 2021Article
- Cell-free DNA from cerebrospinal fluid can be used to detect theTranslational lung cancer research · 2021Article
- Plasma Concentrations of Extracellular DNA in Acute Kidney Injury.Diagnostics (Basel, Switzerland) · 2020Article
- Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA.Nature communications · 2018Article
- Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay.PloS one · 2018Article
- Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.European journal of cancer (Oxford, England : 1990) · 2018Article
- NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Review
- Effect of blood pressure and glycemic control on the plasma cell-free DNA in hemodialysis patients.Kidney research and clinical practice · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Circulating free nucleic acids, known as cell-free DNA (cfDNA), have been proposed as a novel biomarker of cardiovascular risk. The impact of renal impairment on cfDNA levels and whether cfDNA is associated with endothelial dysfunction and inflammation in CKD has not been systematically studied. We analysed cfDNA concentrations from patients with varying degrees of CKD. In addition, to determine whether there is a relationship between cfDNA, inflammation, and endothelial dysfunction in CKD, levels of proinflammatory cytokines and von Willebrand Factor (vWF) were measured in patients treated with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone or placebo for 8 weeks. cfDNA levels were not increased with renal impairment or associated with the degree of renal dysfunction (P = 0.5). Treatment with rosiglitazone for 8 weeks, but not placebo, was more likely to lead to a reduction in cfDNA levels (P = 0.046); however, the absolute changes in cfDNA concentrations during treatment were not statistically significant (P > 0.05). cfDNA levels correlated with markers of endothelial dysfunction (hsCRP P = 0.0497) and vWF (P = 0.0005). In conclusion, cell-free DNA levels are not influenced by renal impairment but do reflect endothelial dysfunction in patients with CKD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.